Infection with the obligate parasite Toxoplasma gondii is common throughout the world. Fortunately, most infections range from asymptomatic to mild symptoms. ' There are, however, several conditions in which acquired infection or reactivation of latent infections can be life threatening, such as pregnancy, after transplantation, and AIDS. Serological test results in each of these conditions, however, can provide important information for improved patient management.
Infection during pregnancy often results in fetal damage, causing a stillbirth or birth of an infant with congenital toxoplasmosis, the effects of which may not be apparent, for months or even years. 2 Mandatory prenatal serological screening in France has shown that timely diagnosis by seroconversion, rising IgG antibody titres, or the presence of IgM antibody3 followed by prenatal treatment can alleviate the effects of congenital toxoplasmosis. 4 Tgondii antibody negative, immunosuppressed recipients of heart, or heart and lung, transplants from Reproducibility Inter-and intra-assay reproducibility were determined by performing 10 runs containing the index calibrator, a negative control, and two levels of positive sera in duplicate over 21 days. The index ofeach test sample was calculated by dividing the sample value by the value of a single replicate of the index calibrator.
Sensitivity and specificity The effectiveness of the HGG coated microparticles in removing rheumatoid factor was tested by creating a series of rheumatoid factor positive sera containing increasing titres of IgG antibody to Tgondii in the absence of IgM antiTgondii antibody. Dilutions of a serum highly positive for IgG antibody (1500 IU/ml) were made in a negative serum. One volume of each of the dilutions was mixed with three volumes of a rheumatoid factor positive serum (titre 1/ 1280) resulting in a series of sera containing from 1 to 269 IU/ml IgG antibody to Tgondii in the presence of rheumatoid factor. Each of the sera were tested by both the Toxo IgG and Toxo IgM MEIA, as described previously.
Four hundred and ninety five sera obtained from clinical laboratories in the United States, France, Germany, Italy and Spain were tested by the Toxo IgM MEIA. Sera with an index of 0-5 or greater were treated to adsorb any rheumatoid factor and retested as described previously. Table 2 shows that consistent control and panel results were obtained. As with the Toxo IgG MEIA, the excellent Toxo IgM MEIA intra-assay reproducibility indicates that patient sera may be evaluated on the basis of a single replicate. Out of the remaining 448 sera, 364 were negative by the reference EIA. The MEIA results ranged from 0x092-1*998 with a mean (SD) of 0-292 (0-167) and a median of 0-254. Fourteen (3-8%) of the reference EIA negative sera were greater than 0-600 (range 0-655-1 998) by the Toxo IgM MEIA. Eighty four sera were positive by the reference EIA. Toxo IgM MEIA results ranged from 0-238-4 769 with a mean (SD) of 1-565 (1) and a median of 1-244. Seven (8-3%) of the reference EIA positive sera were less than 0-6 (range 0-238-0-483) by the Toxo IgM MEIA.
Nineteen of the 21 sera giving discordant results between the reference EIA and the Toxo IgM EIA were tested by ISAGA (table  4) . The seven reference EIA positive/MEIA negative sera were positive by ISAGA. Five negative and seven positive ISAGA results were obtained from the 14 reference EIA negative/MEIA positive sera (two were of insuffiicient volume for further testing). The seven ISAGA positive/EIA negative sera were removed from the group of 364 negative sera and considered positive for IgM antibody to T gondii. Ultimately, this resulted in an IgM 
